Jonathan E. Lim, M.D.
Managing Partner and Founder

Jonathan Lim established City Hill Ventures, LLC in December 2010. In March 2011, Jonathan made City Hill’s first investment in Eclipse Therapeutics, Inc., a company he co-founded with Peter Chu and Chris Reyes from Biogen Idec. Under his leadership, first as Executive Chairman, then most recently as Chairman and CEO, Eclipse spun out the cancer stem cell discovery stage assets from Biogen Idec, generated compelling preclinical data, and selected a lead monoclonal antibody candidate. This successfully resulted in the acquisition of the company by Bionomics Ltd (ASX:BNO) and his appointment to Bionomics’ Board of Directors in September 2012. Jonathan currently serves as Chairman and CEO of IGNYTA, Inc., another City Hill portfolio company he co-founded. Prior to City Hill from May 2003 to December 2010, Jonathan was President, CEO, and Board Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO), where he led the company’s growth from a privately held startup with 5 employees to a publicly traded company with 140 employees and peak market capitalization of nearly $1 billion. Under his leadership, the company went public and raised $300 million from financing and corporate partnerships with Roche and Baxter, achieved two U.S. FDA approvals, and built a deep pipeline of late stage clinical drug candidates. Jonathan’s prior experience includes management consulting at McKinsey & Company, NIH Postdoctoral Fellowship at Harvard, and two years of general surgery residency at New York Hospital-Cornell. He has B.S. and M.S. degrees from Stanford, M.D. from McGill, and M.P.H. from Harvard.

Zachary Hornby
Operating Partner

Zachary Hornby serves in operating roles in City Hill portfolio companies and is currently Chief Operating Officer at Ignyta,Inc. He brings over ten years of life sciences business experience to Ignyta. Prior to joining Ignyta, Zach was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Zach has also served in various business and commercial roles at Halozyme Therapeutics, Neurocrine Biosciences and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an M.B.A. from Harvard Business School.

Karen Gilmore, CPA

Karen Gilmore joined City Hill Ventures in early 2011 as Controller and has supported multiple portfolio companies of City Hill including Eclipse Therapeutics, Inc., Ignyta, Inc. and Medenovo. She has over 25 years’ experience in leadership roles in medical device, pharmaceutical, financial services/venture funds, technology and manufacturing. Currently, Karen provides CFO and Controller level consulting to small scale start-ups and small corporations. Karen began her career as an auditor with Coopers & Lybrand (currently PriceWaterhouseCoopers). She has a Bachelor of Science degree from California State Polytechnic University, Pomona and is a Certified Public Accountant.